https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-10-24 17:22:372024-10-24 17:22:372024 ENA (poster): Pulsatile Induction of the p53 Pathway by MDM2 Antagonist ASTX295 Shows an Enhanced Therapeutic Index in vivo
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-10-23 17:11:352024-10-23 17:14:222024 ENA (poster): A Novel Small-Molecule CBP/p300 HAT Domain Inhibitor Demonstrates Potent In Vivo Activity and a Favourable Safety Profile in Preclinical Species
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-10-23 17:10:162024-10-23 17:14:322024 ENA (poster): Targeting the Catalytic HAT Domain of CBP/p300 for the Treatment of Hormone-Dependent Breast and Prostate Cancers
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-10-23 17:07:572024-10-23 17:14:432024 ENA (poster): Identification of Biomarkers Predictive of Response to ASTX295, a Next-Generation MDM2 Antagonist, in Solid Tumors Carrying Wild-type p53
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-10-02 11:27:342024-10-23 17:14:542024 ESMO (poster): Activity of ERK1/2 Inhibitor ASTX029 in Patients with Gynecological Malignancies Harboring Genomic Alterations in the MAPK Pathway
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-06-06 13:21:272024-06-06 14:09:192023 ASH (poster): Epigenetic priming by hypomethylation enhances the immunogenic potential of tolinapant in T-cell lymphoma
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-04-10 13:43:272024-10-23 17:13:112024 AACR (oral): Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile. From concept to clinic.
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-04-09 16:41:102024-04-23 14:22:252024 AACR (poster): Identification of biomarkers of response to MDM2 inhibition in solid tumours using computational, multi-omics approaches.
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-04-09 16:38:192024-04-23 14:20:242024 AACR (poster): Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2024-04-09 16:35:002024-04-23 14:20:332024 AACR (poster): Targeting the MDM2-p53 interaction: Time-and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
